(Q35038450)

5 August 2017

1 reference

title

Deeply invasive candidiasis (English)

1 reference

5 August 2017

1 reference

1 reference

Luis L Ostrosky-Zeichner

series ordinal

1

object named as

Luis Ostrosky-Zeichner

1 reference

5 August 2017

John H Rex

2

1 reference

5 August 2017

John Bennett

series ordinal

3

1 reference

5 August 2017

Bart-Jan Kullberg

series ordinal

4

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Infectious Disease Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

821-835

1 reference

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Epidemiology of candidemia--a nationwide survey in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Invasive candida infections--evolution of a fungal pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Nosocomial candidemia: risk factors and attributable mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fungal Flora of the Normal Human Small and Large Intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Epidemiology of candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Infections caused by aterial catheters used for hemodynamic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Relevance of culturing Candida species from intravascular catheters.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candida colonization and subsequent infections in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candida infections in the surgical intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candida infections in critically ill trauma patients: a retrospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Predictors of adverse outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fungaemia and funguria after oral administration of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Non-albicans Candida species isolated from plastic devices

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Current status of nonculture methods for diagnosis of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Panfungal PCR assay for detection of fungal infection in human blood specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Management of asymptomatic candiduria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fungal infections of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The management of fungal obstructive uropathy in neonates and infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Uncommon causes of peritonitis in patients undergoing peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Treatment of Candida peritonitis by peritoneal lavage with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Preventing intra-abdominal candidiasis in surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Pulmonary disease caused by Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candida infection of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Intraluminal pancreatic candidiasis presenting as recurrent pancreatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Gallbladder and biliary tract candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

A Prospective Search for Ocular Lesions in Hospitalized Patients with Significant Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candidemia, look at the eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candidal infection in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

The treatment of Candida albicans shunt infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Meningitis caused by Candida species: an emerging problem in neurosurgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fungal arthritis. I. Candida arthritis: diagnostic and prognostic implications and therapeutic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Fungal arthritis. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

1 reference

7 January 2021

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Prophylactic antifungal therapy in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Echinocandins and pneumocandins--a new antifungal class with a novel mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900034-X

7 January 2021

10.1016/S0891-5520(02)00034-X

Identifiers

DOI

1 reference

5 August 2017

1 reference